Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of demcizumab added to carboplatin + pemetrexed in first-line stage IV non-squamous non-small cell lung cancer
2014-003356-30Phase 2Completed
- Sponsor
- OncoMed Pharmaceuticals
- Start
- Oct 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of demcizumab in Non-small cell lung cancer (NS-NSCLC) (3 arms), sponsored by OncoMed Pharmaceuticals. Primary endpoint: Investigator-assessed median progression-free survival. Started Oct 2014; status: completed.
02
Drugs
demcizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2014-003356-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003356-30.